AstraZeneca-Merck's Lynparza Wins FDA Approval For Early-Stage Breast Cancer

The FDA has approved AstraZeneca Plc's AZN cancer drug, jointly developed with Merck & Co Inc MRK to treat patients with early-stage breast cancer with certain mutations.

  • The agency approved Lynparza (olaparib) for patients with a form of genetically mutated high-risk early-stage breast cancer called BRCA-mutated HER2-negative, who have already been treated with chemotherapy either before or after surgery.
  • The approval was based on results from a late-stage study. Lynparza showed statistically significant and clinically meaningful improvement in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences and second cancers or death by 42% compared with placebo.
  • New updated results from the OlympiA trial also showed Lynparza demonstrated a statistically significant and clinically meaningful improvement in the key secondary endpoint of overall survival (OS), reducing the risk of death by 32% versus placebo
  • Following the U.S. approval for Lynparza, AstraZeneca will receive a regulatory milestone payment of $175 million from Merck.
  • Separately, the FDA has also approved Myriad Genetics Inc's MYGN BRACAnalysis CDx test as a companion diagnostic to identify patients with germline BRCA-mutated HER2 negative, high-risk early-stage breast cancer who may benefit from Lynparza.
  • Price Action: AZN stock is up 1.61% at $61.27 during the premarket session on the last check Monday. MRK stock closed 0.06% higher at $78.30 during after-hours trading on Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralbreast cancerBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!